• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.66% Nasdaq Up0.88%

    Regulus Therapeutics Inc. (RGLS)

    5.93 Up 0.09(1.54%) 4:00PM EDT
    ProfileGet Profile for:
    Regulus Therapeutics Inc.
    3545 John Hopkins Court
    Suite 210
    San Diego, CA 92121
    United States - Map
    Phone: 858-202-6300
    Website: http://www.regulusrx.com

    Index Membership:N/A
    Full Time Employees:88

    Business Summary 

    Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target RNAs to treat a range of diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. Its clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 to treat nonalcoholic steatohepatitis in patients with type 2 diabetes/pre-diabetes. The company has strategic alliance with GSK to discover and develop microRNA therapeutics for immuno-inflammatory diseases; Sanofi to discover and develop microRNA therapeutics for fibrotic diseases; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and Biogen Inc. to evaluate the use of microRNA signatures as a biomarker for human patients with various sclerosis. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Regulus Therapeutics Inc.

    Corporate Governance 
    Regulus Therapeutics Inc.’s ISS Governance QuickScore as of May 1, 2016 is 8. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 5; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Paul C. Grint M.D., 58
    Chief Exec. Officer, Pres and Director
    Mr. Joseph P. Hagan , 47
    Principal Financial Officer, Chief Operating Officer and Principal Accounting Officer
    Amy Conrad ,
    Sr. Director of Investor Relations and Corp. Communications
    Mr. Christopher Aker J.D.,
    VP of Legal Affairs and Corp. Sec.
    Ms. Mary Glanville ,
    Sr. VP of Human Capital
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders